The material parameters of the 50 MPa concrete for the simulations [26]. by Xiaochao Jin (3993236)

3D snapshots of the tumor system with single-agent BHQ880 treatment at (a) time step 40, (b) time step 50 and (c) time step 120. by Minna Qiao (836556)

Effect of the Hill coefficient on estimates of <i>ε</i>_max (left column) and IC₅₀ (right column) for the logistic model with drug applied to the growth rate <... by Hope Murphy (8843516)

Dimerization of [Fe^III(bpy)₃]³⁺ in Aqueous Solutions: Elucidating a Mechanism Based on Historical Proposals, Electrochemical Data, and Computationa... by Nicolas E. Holubowitch (9254254)

“…Despite these favorable characteristics, its oxidized Fe­(III) form undergoes dimerization to form μ-O-[Fe^III(bpy)₂(H₂O)]₂⁴⁺, leading to a dramatic ∼0.7 V decrease during battery discharge. …”

Test characteristics for identifying stenosis ≥ 50% in any limb from aorta till popliteal artery in the overall population (<i>n = 126 limbs</i>). by O. Stivalet (6890189)

Fig 3 - by Yan Shu (441370)

TLC photography of fungal extract. by Shivankar Agrawal (11565095)

Subjects:

[Na⁺]_i is decreased in SLO3 mutant sperm and in sperm treated with the SLO3 inhibitor clofilium. by Julio C. Chávez (399841)

Fig 5 - by Shivankar Agrawal (11565095)

Subjects:

Circadian Genes, <i>xBmal1</i> and <i>xNocturnin</i>, Modulate the Timing and Differentiation of Somites in <i>Xenopus laevis</i> by Kristen L. Curran (95520)

“…We observed opposing effects on somite size. Depletion of xBMAL1 or xNOCTURNIN caused a statistically significant decrease in somite area (quantified using NIH ImageJ; p<0.002), while overexpression of these proteins caused a significant dose dependent increase in somite area (p<0.02; p<0.001, respectively). …”

Decreased vessel number and increased vessel caliber in <i>Fzd4</i>^+/- mice after ocular ischemic retinopathy. by Michael H. Ngo (3143202)

hMSC adjunctive therapy failed to decrease pulmonary inflammation or prevent ALI compared to antiviral therapy alone in experimental severe influenza. by Ilyse Darwish (446378)

“…<p>Eight-week old male C57Bl/6 mice infected with 425 EID₅₀ influenza A/PR/8 virus were administered 2.5 mg/kg oseltamivir in 100 ul ddH2O via gavage, 1×daily for 5 days, beginning day 2 P.I., with or without hMSC administration (5×10⁵ cells) on day 2 P.I. and sacrificed on day 7 P.I. …”

Blocking CD4, integrins, and lectins simultaneously significantly decreased DC binding and uptake of both free and complement opsonized HIV-1. by Veronica Tjomsland (210021)

Microparticles Engineered to Highly Express Peroxisome Proliferator-Activated Receptor-γ Decreased Inflammatory Mediator Production and Increased Adhesion of Recipient Monocytes by Julie Sahler (666499)

Identification of Gut Microbiota Biomarker Genera Distinguishing Wild and Captive Animals (A) Top 50 discriminative genera selected by random forest classifier, ranked by mean decrease accuracy. by Lin Xu (94491)

Long-Term Effects of Botulinum Toxin Complex Type A Injection on Mechano- and Metabo-Sensitive Afferent Fibers Originating from <i>Gastrocnemius</i> Muscle by Guillaume Caron (816032)

“…After toxin injection, we observed a complete paralysis associated to a loss of force to muscle stimulation and a significant muscle atrophy, and a return to baseline when the animals recover. …”

The human neutrophil IL-1β secretory response, in contrast to the CXCL8/IL-8 secretory response decreases as MOI increases. by Florencia Sabbione (4862455)

Decreased s.c. growth of CNDT 2.5 cells after systemic administration of DOPC liposome-conjugated siNRP-2. by Shaija Samuel (341436)

Development of (2-(Benzyloxy)phenyl)methanamine Derivatives as Potent and Selective Inhibitors of CARM1 for the Treatment of Melanoma by Zhihao Liu (419349)

“…In our previous study, we have identified a series of type I PRMT inhibitors, among which ZL-28-6 (<b>6</b>) exhibited increased activity against CARM1 while displaying decreased potency against other type I PRMTs. …”

Development of (2-(Benzyloxy)phenyl)methanamine Derivatives as Potent and Selective Inhibitors of CARM1 for the Treatment of Melanoma by Zhihao Liu (419349)

“…In our previous study, we have identified a series of type I PRMT inhibitors, among which ZL-28-6 (<b>6</b>) exhibited increased activity against CARM1 while displaying decreased potency against other type I PRMTs. …”